Advancing Metabolic Disease Research with Precision and Integrated Insight

Metabolic diseases involve interconnected biological pathways, including metabolism, inflammation, and fibrosis. This complexity requires you to measure multiple biomarkers over time while accounting for patient heterogeneity and slow disease progression. Generating meaningful insights depends on integrating longitudinal data and selecting biomarkers that sensitively reflect treatment impact.

We help you design biomarker strategies that align with your study objectives and endpoints. By combining multi-omic technologies, bioanalytical assays, and tissue-based approaches, we generate complementary datasets that provide a more complete view of disease biology. Our scientific teams support assay selection, validation, and data integration to ensure your results are robust, consistent, and clinically relevant.

Yes. We provide end-to-end support for NASH and liver-focused studies, from biopsy handling and processing through to scoring and digital pathology. Our expertise includes fibrosis and steatosis assessment, validated staining workflows, and AI-assisted image analysis. This enables consistent, reproducible evaluation of tissue endpoints across global studies.

Yes. We operate a globally harmonized laboratory network designed to deliver consistent testing and data across regions. Standardized workflows, integrated data management, and regional expertise allow you to scale your study while maintaining data quality, regulatory compliance, and operational efficiency.

Engaging early allows you to define the right biomarker strategy from the outset. We work with you to align assay selection, study design, and analytical approaches with your objectives, reducing the risk of rework and ensuring your data supports key clinical and regulatory decisions throughout development.